Disclaimer
This pocket guide a empts to define principles of prac ce that should produce high-quality
pa ent care. It is applicable to specialists, primary care providers and ancillary healthcare
providers. This pocket guide should not be considered exclusive of other methods of care
reasonably directed at obtaining the same results. The ul mate judgment concerning the
propriety of any course of conduct must be made by the clinician a er considera on of each
individual pa ent situa on.
Neither IGC, SITC, nor the authors endorse any product or service associated with the
distributor of this clinical reference tool.
Abbrevia ons
ADT, androgen depriva on therapy; AS, ac ve surveillance; mCRPC; metasta c castra on-
resistant prostate cancer; PSA, prostate-specific an gen; RP, radical prostatectomy; RT,
radia on therapy
Source
McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan
RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN,
Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on
immunotherapy for the treatment of prostate carcinoma. Journal for ImmunoTherapy of
Cancer 2016;4:92.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2018 All rights reserved
SITCPRO1834a_den
Defini on of Evidence Grades
Level Defini on
A Strong suppor ng evidence-based data from prospec ve, randomized,
controlled trials, meta-analyses, long-term follow-up of prospec ve,
uncontrolled trials
B Moderate suppor ng data from uncontrolled, prospec ve clinical trials
C Weak suppor ng data from retrospec ve reviews and case reports
Percentages Propor on of Task Force members favoring recommenda on
